Company profile: IOmet Pharma
1.1 - Company Overview
Company description
- Provider of novel small-molecule medicines for the treatment of cancer, discovered and developed in the UK with particular emphasis on cancer immunotherapy and cancer metabolism.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to IOmet Pharma
Complix
HQ: Belgium
Website
- Description: Provider of Alphabody biopharmaceuticals focused on discovering and developing a novel class of therapeutics that bind with high affinity to disease targets. Offerings include Cell Penetrating Alphabodies to modulate intracellular protein interactions, a pipeline for intracellular targets in cancer, autoimmunity, and viral diseases, and anti-Covid-19 Alphabodies targeting SARS-CoV-2 fusion for prophylactic and therapeutic use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Complix company profile →
Xstrahl
HQ: United States
Website
- Description: Provider of superficial orthovoltage X-ray systems for treating skin and bone cancers, dermatological disorders, benign conditions, and for palliative care, with precise non-surgical options. Also offers a compact office-based dual-modality device for non-melanoma skin cancers and keloid scarring, and advanced X-ray platforms for preclinical radiation biology research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xstrahl company profile →
Immune-Onc Therapeutics
HQ: United States
Website
- Description: Provider of therapeutic antibodies for cancer treatment, developing IO-202, a humanized IgG1 targeting LILRB4 to deplete LILRB4-expressing cells in blood cancers, autoimmune, and inflammatory diseases; IO-108, a fully human IgG4 targeting LILRB2 to block cancer-associated immune suppression in solid tumors; and IO-312, a bispecific targeting LILRB4 and CD3 for AML and other hematologic malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immune-Onc Therapeutics company profile →
PCI Biotech
HQ: Norway
Website
- Description: Provider of photochemical drug delivery technologies for cancer therapy, focusing on photochemical internalisation (PCI) to enhance intracellular delivery of therapeutic compounds for novel cancer treatments, and photochemical lysis (PCL) to improve viral vector manufacturing through light-triggered cell lysis that increases yield and reduces impurities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PCI Biotech company profile →
Piramed
HQ: United Kingdom
Website
- Description: Provider of inhibitor-focused drug discovery and development of new medicines targeting cancer and immune inflammatory disorders, with applications across cardiovascular disease and pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Piramed company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for IOmet Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to IOmet Pharma
2.2 - Growth funds investing in similar companies to IOmet Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for IOmet Pharma
4.2 - Public trading comparable groups for IOmet Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →